H.C. Wainwright Reiterates Buy Rating on Assertio Therapeutics (ASRT)

March 18, 2026 7:54 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $35.00 price target on Assertio Therapeutics (NASDAQ: ASRT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found